Is Teladoc a strong buy?

Relative to the highs of early 2021, Teladoc Health has now dropped by around 90% -- this means that those that bought at the highs would have to see a 900% share price increase from current levels just to break even.

Is Teladoc a good buy now?

Teladoc Health, Inc. (NYSE:TDOC) delivered a -39.02% return since the beginning of the year, while its 12-month returns are down by -67.23%. The stock closed at $55.99 per share on April 25, 2022. "Teladoc is the largest telehealth provider in the US and has recently begun to expand internationally.

What is the future of Teladoc stock?

First, the company expects its net loss to continue shrinking. For fiscal 2022, Teladoc projected it would report a net loss per share between $1.60 and $1.40. At this rate, Teladoc could become profitable by 2024.

Who is Teladoc biggest competitor?

Amwell (NYSE: AMWL), formerly known as American Well, is a telemedicine company founded in 2006 and went public in 2020. It is currently the biggest competitor to Teladoc in the telehealth space and has experienced significant growth in recent years.

Will Teladoc ever be profitable?

The telehealth giant isn't yet profitable and reported a loss of $84.3 million in the third quarter of 2021, deeper than its year-prior loss of $36 million. Shares of Teladoc stock fell 6.2% on Monday as of 10:47 a.m. in New York.

Teladoc to Trillions: I’m All In

Will Teladoc continue to grow?

Key Points. Teladoc is still growing its revenue, earnings, and member count. Its strong financials put it in a great position to pursue more growth opportunities. With the stock down heavily, now may be an optimal time to buy it.

Is Teladoc going under?

Shares of struggling telehealth company Teladoc Health (TDOC 4.03%) collapsed after it recently released earnings for the first quarter of 2022. After shooting to roughly $300 per share in early 2021, the stock sits at just under $40, a staggering decline of more than 80%.

Why is Teladoc going down?

What happened. Shares of Teladoc Health (TDOC 3.57%) went down in flames on Thursday, plunging as much as 47.8%. At 10:28 a.m. ET, the stock was down 46.3%. The catalyst that sent the digital healthcare company plummeting was first-quarter financial results that were far worse than investors had anticipated.

Which telemedicine company is best?

What company owns Teladoc?

The Vanguard Group, Inc. Baillie Gifford & Co. Nikko Asset Management Co., Ltd.

Is Teladoc a good long term investment?

Teladoc has a first-mover advantage in this field and is poised for a rosy future. Beyond that, the telehealth company boasts excellent financial performance. In 2021, Teladoc's total revenue jumped 86% year over year (YOY) to reach $2 billion.

Will Teladoc ever recover?

Despite the stock's steady decline over the past year, Teladoc Health still holds a promising future due to its disruptive model. According to Tulane University School of Public Health and Tropical Medicine, Telemedicine is here to stay for the foreseeable future.

How high will Teladoc stock go?

Stock Price Forecast

The 24 analysts offering 12-month price forecasts for Teladoc Health Inc have a median target of 43.50, with a high estimate of 141.00 and a low estimate of 30.00.

Is Teladoc undervalued?

The revenue per member was reported $2.32 in 2021, up from $1.12 in 2020. I believe Teladoc's stock price is undervalued based on relative valuation indicators. The stock's price-to-sales ratio hit below 4 in mid-March (lowest since 2016) and is trading at 5.33, while the price-to-book ratio is at 0.69.

Is TDOC a Buy Sell or Hold?

Out of 27 analysts, 6 (22.22%) are recommending TDOC as a Strong Buy, 5 (18.52%) are recommending TDOC as a Buy, 16 (59.26%) are recommending TDOC as a Hold, 0 (0%) are recommending TDOC as a Sell, and 0 (0%) are recommending TDOC as a Strong Sell. What is TDOC's earnings growth forecast for 2022-2024?

Is teladoc health a Buy Sell or Hold?

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 18 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Teladoc Health stock.

Who are Teladoc competitors?

Teladoc Health's top competitors include naviHealth, Lash Group, Amwell, 98point6, MDLIVE, Providence Service Corporation and Sharecare. Teladoc Health is a telehealth company that uses telephone and video conferencing technology to provide on-demand remote medical care via mobile devices, the internet, and video.

Who are AmWell's competitors?

Is Teladoc an acquisition target?

As a reader, you need to bear in mind that Teladoc is an acquisition vehicle; we thus need to consider that its "struggle towards profitability" has been down to transitory costs rather than a flawed business model.

Why did Teladoc stock tank?

TDOC stock has seen its value tank in the past year due to the market's overreaction. Teladoc Health has a strong moat, healthy fundamentals and an incredible outlook to boot, unlike most coronavirus stocks. TDOC stock was down over 75% from its peak price of $249 in August 2020.

Will TDOC rise again?

TDOC's management is somewhat more positive with its early guidance expectations for 2022, as revenue is forecasted to rise by around 27% (according to Wall Street estimates).

What was teladoc IPO price?

Telehealth platform company Teladoc, on Tuesday, announced that its initial public offering would be priced at $19 per share, raising $157 million, according to a Renaissance Capital post to NASDAQ.com.